Relationships between monocyte chemotactic protein 1 and periosteal protein levels and prognosis in patients with acute myocardial infarction after PCI

doi:10.3760/cma.j.issn.1007-1245.2024.24.021

Abstract

Abstract:

Objective　To evaluate the relationships between monocyte chemotactic protein-1 (MCP-1) and periosteal protein levels and prognosis in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Methods　In this study, 106 patients with AMI who underwent PCI in Xingyuan Hospital of Yulin from March 2021 to January 2024 were included. Based on the occurrence of major adverse cardiovascular events (MACE) within 3 months after surgery, the patients were divided into a poor prognosis group and a good prognosis group. The levels of MCP-1 and periosteal protein were measured by enzyme-linked immunosorbent assay (ELISA) after PCI, and the levels of MCP-1 and periosteal protein in patients with different prognosis were compared. Spearman rank correlation analysis and logistic regression model were used to analyze the correlations between MCP-1 and periosteal protein levels and prognosis in AMI patients after PCI. The receiver operating characteristic curve (ROC) was drawn to analyze MCP-1 and periosteal protein in predicting the prognosis in AMI patients after PCI. Independent sample t test and χ² test were used for statistical analysis. Results　In the good prognosis group, there were 44 males and 31 females, aged (65.43±5.76) years, with a body mass index of (23.07±0.97) kg/m². In the poor prognosis group, there were 19 males and 12 females, aged (65.02±5.41) years, with a body mass index of (22.86±0.86) kg/m². The levels of MCP-1 and periosteal protein in the poor prognosis group were higher than those in the good prognosis group [(35.57±3.65) ng/L vs. (29.66±3.52) ng/L, (155.12±12.19) μg/L vs. (142.03±10.43) μg/L], with statistically significant differences (both P<0.05). Correlation analysis showed that both MCP-1 and periosteal protein were positively correlated with poor prognosis (r=0.594 and 0.444, both P<0.05). Logistic regression analysis showed that both MCP-1 and periosteal protein were risk factors for poor prognosis (OR=1.615 and 1.119, both P<0.05). ROC analysis showed that the areas under the curves (AUCs) of MCP-1 and periosteal protein alone were 0.877 and 0.782, respectively. When MCP-1 and periosteal protein were used in combination, the AUC increased to 0.929, the sensitivity and specificity were 87.1% and 86.7%, respectively, and the Yoden index was 0.738. Conclusions　MCP-1 and periosteal protein levels are closely related to the prognosis of AMI patients after PCI, and can be used as biomarkers for predicting poor prognosis. These findings support the use of MCP-1 and periosteal protein as potential tools for assessing risk and treatment response in AMI patients in clinical practice.

Key words:

Acute myocardial infarction, Percutaneous coronary intervention, Monocyte chemotactic protein 1, Periosteal protein, , Prognosis

摘要：

目的　评估单核细胞趋化蛋白1（MCP-1）和骨膜蛋白水平与经皮冠状动脉介入治疗（PCI）术后急性心肌梗死（AMI）患者预后的关系。方法　本研究纳入2021年3月至2024年1月榆林市星元医院106例接受PCI的AMI患者，基于术后3个月内的主要不良心血管事件（MACE）发生情况，将患者分为预后不良组和预后良好组。通过酶联免疫吸附试验（ELISA）测定患者PCI术后MCP-1及骨膜蛋白水平，比较不同预后组患者MCP-1及骨膜蛋白水平，采用Spearman秩相关分析及logistic回归模型分析MCP-1、骨膜蛋白水平与PCI术后AMI患者预后的相关性，绘制受试者操作特征曲线（ROC）分析MCP-1、骨膜蛋白评估PCI术后AMI患者预后的价值。采用独立样本t检验、χ²检验进行统计学分析。结果　预后良好组75例，其中男44例，女31例，年龄（65.43±5.76）岁，体重指数（23.07±0.97）kg/m²。预后不良组31例，其中男19例，女12例，年龄（65.02±5.41）岁，体重指数（22.86±0.86）kg/m²。预后不良组的MCP-1和骨膜蛋白水平均高于预后良好组［（35.57±3.65）ng/L比（29.66±3.52）ng/L，（155.12±12.19）μg/L比（142.03±10.43）μg/L］，差异均有统计学意义（均P<0.05）。相关性分析显示，MCP-1和骨膜蛋白与预后不良均呈正相关（r=0.594、0.444，均P<0.05）。logistic回归分析表明，MCP-1及骨膜蛋白水平均为预后不良的危险因素（OR=1.615、1.119，均P<0.05）。ROC分析显示，单独使用MCP-1和骨膜蛋白的曲线下面积（AUC）分别为0.877和0.782，两者联合使用时，AUC提升至0.929，灵敏度和特异度分别为87.1%和86.7%，约登指数为0.738。结论　MCP-1和骨膜蛋白水平与PCI术后AMI患者预后密切相关，可以作为判断预后不良的生物标志物。这些发现支持在临床实践中使用MCP-1和骨膜蛋白作为评估AMI患者风险和治疗反应的潜在工具。

关键词:

急性心肌梗死, 经皮冠状动脉介入治疗, 单核细胞趋化蛋白1, 骨膜蛋白, 预后

Liu Jianjian, Du Pengrong, Wang Rui.

Relationships between monocyte chemotactic protein 1 and periosteal protein levels and prognosis in patients with acute myocardial infarction after PCI [J]. International Medicine and Health Guidance News, 2024, 30(24): 4166-4170.

刘建建杜鹏荣王蕊.

单核细胞趋化蛋白1、骨膜蛋白与PCI术后急性心肌梗死患者预后的关系 [J]. 国际医药卫生导报, 2024, 30(24): 4166-4170.

References

[1] Lu R, Lin W, Jin Q, et al. Plasma metabolic profiling and multiclass diagnostic model development for stable angina pectoris and acute myocardial infarction[J]. ACS Omega, 2024, 9(14):16322-16333. DOI: 10.1021/acsomega.3c10474.
[2] Wang CM, Su TT, Yue Y, et al. Relationship between heart rate variability parameters and short-term prognosis of patients with acute myocardial infarction[J]. J Coll Physicians Surg Pak, 2024, 34(4):468-473. DOI: 10.29271/jcpsp.2024.04.468.
[3] Shakir FTA. Is there a correlation between monocyte chemoattractant protein-1 with autotaxin, azurocidin-1, apolipoprotein C-III and elastase-2 in male Iraqi acute myocardial infraction patients?[J]. Biomedical and Pharmacology Journal, 2019, 12(4): 2105-2121. DOI: 10.13005/bpj/1846.
[4] Liu N, Sheng J, Wang Y. Effect of stress hyperglycaemia on monocyte chemoattractant protein-1 levels and the short-term prognosis of patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Exp Ther Med, 2019, 17(5):3823-3829. DOI: 10.3892/etm.2019.7338.
[5] 李正.血清CysC、RLX、Periostin、Copeptin水平对AMI患者 PCI术后预后的预测价值[J].心血管康复医学杂志,2018,27(4):406-410. DOI:10.3969/j.issn.1008-0074. 2018.04.10.
[6] Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines[J]. Circulation, 2021, 144(22):e368-e454. DOI: 10.1161/CIR.0000000000001030.
[7] 中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400. DOI:10.3760/cma.j.issn.0253-3758.2016.05.006.
[8] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. DOI:10.3760/j.issn:0253-3758.2007.04.003.
[9] 范利斌,范乾晖,范松,等.24 h动态心电图参数对急性心肌梗死患者恶性室性心律失常的诊断价值[J].山东医药,2023,63(1):65-68. DOI:10.3969/j.issn.1002- 266X.2023.01.016.
[10] 徐佰达,陈可,刘叶红,等.血清生长分化因子11水平与急性心肌梗死患者冠脉病变严重程度的相关性[J].中华心血管病杂志,2024,52(3):286-292. DOI:10.3760/cma.j.cn112148-20230715-00005.
[11] 王青雷,付珊,李舒承,等.TET2基因单核苷酸多态性与急性心肌梗死易感性的关系[J].中国现代医学杂志,2023,33(7):15-19. DOI:10.3969/j.issn.1005-8982.2023.07.003.
[12] 王珍,申国旗,李亚南,等.急性心肌梗死患者行经皮冠状动脉介入治疗术后发生对比剂急性肾损伤风险预测模型的建立与验证研究[J].中国全科医学,2023,26(29):3650-3656. DOI:10.12114/j.issn.1007-9572.2023.0139.
[13] 李晶瑾,翟阳,靳刚,等.急性心肌梗死患者外周血单个核细胞miR-132、单核细胞趋化蛋白-1的表达及与预后的关系[J].贵州医科大学学报,2022,47(1):106-113. DOI:10.19367/j.cnki.2096-8388.2022.01.018.
[14] 汪丽丽,贺钰梅,张永莉.急性心肌梗死患者血清超敏C反应蛋白、单核细胞趋化蛋白-1表达及临床意义[J].国际检验医学杂志,2017,38(9):1259-1261. DOI:10.3969/j.issn.1673-4130.2017.09.041.
[15] 方学升,包明威.骨膜蛋白在心血管疾病中的研究进展[J].生物技术进展,2023,13(5):725-729. DOI:10.19586/j.2095-2341.2023.0085.
[16] 王丽,何艺,冉华,等.术前小剂量替罗非班改善急性冠脉综合征患者PCI治疗预后情况的临床研究[J].海南医学院学报,2016,22(11):1058-1061,1065. DOI:10.13210/j.cnki.jhmu.20160301.002.
[17] 苏丹,王博.急性心肌梗死患者经皮冠状动脉介入治疗近期预后的影响因素分析[J].中华生物医学工程杂志,2021,27(6):661-666. DOI:10.3760/cma.j.cn115668-20210818- 00213.
[18] 许梦阅,王洪如.急性ST段抬高型心肌梗死患者血清白介素18、单核细胞趋化因子1水平及其与预后的关系[J].实用心脑肺血管病杂志,2022,30(5):25-29. DOI:10.12114/j.issn.1008-5971.2022.00.077.
[19] 陈心涛,王丁仓,王彦鹤.急性冠状动脉综合征患者PCI前后血清骨膜蛋白水平变化及其与长期预后的相关性[J].中国老年学杂志,2018,38(20):4875-4877. DOI:10.3969/j.issn.1005-9202.2018.20.005.
[20] Combes A, Price S, Levy B. What's new in VA-ECMO for acute myocardial infarction-related cardiogenic shock[J]. Intensive Care Med, 2024, 50(4):590-592. DOI: 10.1007/s00134-024-07356-0.
[21] Buyukkaya E, Poyraz F, Karakas MF, et al. Usefulness of monocyte chemoattractant protein-1 to predict no-reflow and three-year mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Am J Cardiol, 2013, 112(2):187-193. DOI: 10.1016/j.amjcard.2013. 03.011.